B7-H3-targeted CAR-T cell therapy for solid tumors

Area of Science:

• Immunology
• Oncology

Background:

• B7-H3 is overexpressed in various solid tumors, making it a promising target for immunotherapy.
• Restricted expression in normal tissues enhances B7-H3's potential as a specific therapeutic target.

Approach:

• This review focuses on the structural design of chimeric antigen receptors (CARs) targeting B7-H3.
• It discusses B7-H3 expression, receptor function, and monoclonal antibody therapies.
• Summarizes preclinical and clinical data on B7-H3-targeted CAR-T and CAR-NK cell therapies.

Key Points:

• B7-H3-targeted CAR-based cell therapies have demonstrated safety in early trials.
• Initial clinical trials indicate limited efficacy for B7-H3-targeted CAR cell therapies in solid tumors.
• Current research explores enhancing CAR T-cell persistence and combining therapies.

Conclusions:

• B7-H3 is a viable immunotherapeutic target for solid tumors.
• Improving CAR T-cell therapy efficacy requires strategies such as local delivery and combination treatments.
• Further research into CAR-T and CAR-NK cell modifications is crucial for advancing B7-H3-targeted cancer treatments.